ACADIA Pharmaceuticals Inc. (ACAD)
收市後：
| 前收市價 | 16.31 |
| 開市 | 16.42 |
| 買盤 | 16.69 x 500 |
| 賣出價 | 16.72 x 1100 |
| 今日波幅 | 16.26 - 16.74 |
| 52 週波幅 | 16.16 - 33.99 |
| 成交量 | |
| 平均成交量 | 1,789,612 |
| 市值 | 2.753B |
| Beta 值 (5 年，每月) | 0.39 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.37 |
| 業績公佈日 | 2024年5月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 29.29 |
InvestorPlace3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmaceutical firms are grappling with patent cliffs, where key drug exclusivities are expiring. This opens the door for generic competition. Moreover, with the broader market presenting attractive investment options, holding on to these riskier pharma plays could result in significant opportunity cost. Many pro
- InvestorPlace
3 Pharma Stocks to Sell in March Before They Crash & Burn
Recent trends in the stock market have seen a shift in investor interest from tech giants, known as the Magnificent 7, towards pharmaceutical companies, particularly those involved in weight-loss drugs. But, it’s important to identify which pharma stocks to sell before they plummet, as not all will benefit equally from the hype. As a result, pharmaceutical companies like Eli Lilly (NYSE:LLY), Pfizer (NYSE:PFE) and Novo Nordisk (NYSE:NVO) are attracting retail investors’ attention given their por
Investor's Business DailyAcadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients.
